GlaxoSmithKline Plc - Product Pipeline Review - 2015 - Product Image

GlaxoSmithKline Plc - Product Pipeline Review - 2015

  • ID: 3440653
  • Company Profile
  • 436 pages
  • Global Markets Direct
  • GlaxoSmithKline PLC
1 of 4
GlaxoSmithKline Plc - Product Pipeline Review - 2015

Summary

The report ‘GlaxoSmithKline plc - Product Pipeline Review - 2015’, provides an overview of the GlaxoSmithKline plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GlaxoSmithKline plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GlaxoSmithKline plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GlaxoSmithKline plc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GlaxoSmithKline plc’s pipeline products

Reasons to buy

- Evaluate GlaxoSmithKline plc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GlaxoSmithKline plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GlaxoSmithKline plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GlaxoSmithKline plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlaxoSmithKline plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GlaxoSmithKline plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

GlaxoSmithKline Plc Snapshot

GlaxoSmithKline Plc Overview

Key Information

Key Facts

GlaxoSmithKline Plc - Research and Development Overview

Key Therapeutic Areas

GlaxoSmithKline Plc - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

GlaxoSmithKline Plc - Pipeline Products Glance

GlaxoSmithKline Plc - Late Stage Pipeline Products

GlaxoSmithKline Plc - Clinical Stage Pipeline Products

GlaxoSmithKline Plc - Early Stage Pipeline Products

GlaxoSmithKline Plc - Unknown Stage Pipeline Products

GlaxoSmithKline Plc - Drug Profiles

GSK-257049

GSK-2696273

meningococcal meningitis [serotype B] vaccine

mepolizumab

(fluticasone furoate + vilanterol trifenatate)

(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)

albiglutide

alitretinoin

ambrisentan

belimumab

bupropion hydrochloride ER

ebola [strain zaire] vaccine

fluticasone furoate

GSK-1437173A

GSK-2132231A

KD-295

losmapimod

measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine

ofatumumab

recMAGE-A3 + AS15

retosiban

tafenoquine succinate

vilanterol trifenatate

zanamivir

(fluticasone furoate + levocabastine hydrochloride)

afuresertib hydrochloride

batefenterol

CAD-106

camicinal

danirixin

daprodustat

fluticasone furoate + umeclidinium bromide

gepotidacin mesylate

GSK-1070806

GSK-2189242A

GSK-2231392A

GSK-2245035

GSK-2256098

GSK-2269557

GSK-2302032A

GSK-2330672

GSK-239512

GSK-2586881

GSK-2696274

GSK-2696275

GSK-2789869A

GSK-2798745

GSK-2830929A

GSK-2830930A

GSK-2838504-A

GSK-2862277

GSK-2890457

GSK-3003891A

GSK-3196165

GSK-598809

GSK-692342

GSK-732462

GSK-933776

levocabastine hydrochloride

malaria vaccine

mapatumumab

maribavir

meningococcal [serotypes A, B, C, Y and W-135] (pentavalent) vaccine

Nimenrix

otelixizumab

ozanezumab

ProCvax

respiratory syncytial virus vaccine

rilapladib

streptococcal pneumoniae vaccine

streptococcus [serogroup B] (trivalent) vaccine

trametinib dimethyl sulfoxide + dabrafenib mesylate + panitumumab

trametinib dimethyl sulfoxide + uprosertib

umeclidinium bromide

afuresertib hydrochloride + trametinib dimethyl sulfoxide

GSK-2302025A

GSK-2636771

GSK-525762

HIV [strains C1086, TV1] (bivalent) vaccine

pazopanib hydrochloride + pembrolizumab

TDEN-PIV

(amlodipine besylate + rosuvastatin calcium)

(candesartan cilexetil + hydrochlorothiazide)

1790GAHB

diphtheria + pertussis (acellular) + tetanus vaccine

EcoXyn-4V

epelsiban besylate

exenatide

extraintestinal pathogenic escherichia coli vaccine

FMP-010

FP-1039

GLPG-0555

GSK-1070916A

GSK-1940029

GSK-2130579A

GSK-2241658A

GSK-2256294

GSK-2315698 + GSK-2398852

GSK-2330811

GSK-2398852

GSK-2578215A

GSK-2618960

GSK-2646264

GSK-2654909A

GSK-2654911A

GSK-2789868A

GSK-2800528

GSK-2816126

GSK-2831781

GSK-2838497A

GSK-2838500A

GSK-2838501A

GSK-2849330

GSK-2857916

GSK-2878175

GSK-2879552

GSK-2881078

GSK-2981710

GSK-2982772

GSK-3117391

GSK-3174998

GSK-3206640A

GSK-3206641A

GSK-3277509A

GSK-3277510A

GSK-3389245A

GVXNSD-133

HIV vaccine

human immunodeficiency virus vaccine

IMP-731

influenza [strain H5N1] vaccine

montelukast sodium

omipalisib

RSV-001

seasonal influenza vaccine

Staphylococcus aureus vaccine

TerCvax

uprosertib

meningococcal [serotypes A, C, Y and W-135] (quadrivalent) vaccine

Antibody Drug Conjugates for Cancer

BLyS-gel

candida vaccine

Cell Therapy to Target Flt3L for Autoimmune Myocarditis

Gene Therapy to Activate Collagen Type VII for Recessive Dystrophic Epidermolysis Bullosa

GSK-2041706

GSK-214096

GSK-2225745

GSK-2394002

GSK-2656157

GSK-2795039

GSK-6288B

GW-610742

HIV/AIDS vaccine

Influenza Vaccine

marburg vaccine

meningitis vaccine

meningococcal meningitis vaccine

Monoclonal Antibodies to Agonize OX40 Receptors for Cancer

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis

Small Molecule 1 for Malaria

Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer

Small Molecule 2 for Malaria

Small Molecule 2 for Tuberculosis

Small Molecule 2 to Inhibit Histone Methyltransferase for Cancer

Small Molecule 3 to Inhibit Histone Methyltransferase for Cancer

Small Molecule for Hypertension and Insulin Resistance

Small Molecule to Activate AMPK for Type 2 Diabetes

Small Molecules to Inhibit InhA for Tuberculosis

Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis

Staphylococci aureus vaccine

streptococci pneumoniae vaccine

streptococcus [serotype A] vaccine

TC-2153

tuberculosis vaccine

Vaccine for Alzheimer's Disease

Vaccine for Alzheimers Disease

Vaccine for Cancer

Antisense Oligonucleotides for Undisclosed Indication

bacterial (multivalent) vaccine

bacterial vaccine

Drug for Chronic Liver Disease

Drug to Antagonize T-Cell Receptor for Cancer

Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis

enterotoxigenic escherichia coli vaccine

GSK-137647A

GSK-343

GSKJ-1

Monoclonal Antibodies to Modulate Inducible T-cell Costimulator for Cancer

Proteins for Musculoskeletal Disorders

Pseudomonas aeruginosa vaccine

Small Molecule for Tuberculosis

Small Molecule to Antagonize FFA4 for Undisclosed Indication

Small Molecule to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology

Small Molecule to Inhibit BRPF1 for Undisclosed Indication

Small Molecule to Inhibit Histone Deacetylases for Cancer

Small Molecules for HIV-1 Infection

Small Molecules for Tuberculosis

Small Molecules for Undisclosed Indication

Small Molecules to Inhibit Falcipain for Malaria

Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis

Small Molecules to Inhibit RNA Polymerase for Hepatitis C

streptococcus pyogenes vaccine

west nile virus vaccine

typhoid and paratyphoid fever vaccine

GlaxoSmithKline Plc - Pipeline Analysis

GlaxoSmithKline Plc - Pipeline Products by Target

GlaxoSmithKline Plc - Pipeline Products by Route of Administration

GlaxoSmithKline Plc - Pipeline Products by Molecule Type

GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action

GlaxoSmithKline Plc - Recent Pipeline Updates

GlaxoSmithKline Plc - Dormant Projects

GlaxoSmithKline Plc - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

GlaxoSmithKline Plc - Company Statement

GlaxoSmithKline Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

GlaxoSmithKline Plc - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

GlaxoSmithKline Plc, Key Information

GlaxoSmithKline Plc, Key Facts

GlaxoSmithKline Plc - Pipeline by Indication, 2015

GlaxoSmithKline Plc - Pipeline by Stage of Development, 2015

GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2015

GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2015

GlaxoSmithKline Plc - Partnered Products in Pipeline, 2015

GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2015

GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2015

GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015

GlaxoSmithKline Plc - Pre-Registration, 2015

GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2015

GlaxoSmithKline Plc - Phase III, 2015

GlaxoSmithKline Plc - Phase II, 2015

GlaxoSmithKline Plc - Phase I, 2015

GlaxoSmithKline Plc - IND/CTA Filed, 2015

GlaxoSmithKline Plc - Preclinical, 2015

GlaxoSmithKline Plc - Discovery, 2015

GlaxoSmithKline Plc - Unknown, 2015

GlaxoSmithKline Plc - Pipeline by Target, 2015

GlaxoSmithKline Plc - Pipeline by Route of Administration, 2015

GlaxoSmithKline Plc - Pipeline by Molecule Type, 2015

GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2015

GlaxoSmithKline Plc - Recent Pipeline Updates, 2015

GlaxoSmithKline Plc - Dormant Developmental Projects,2015

GlaxoSmithKline Plc - Discontinued Pipeline Products, 2015

GlaxoSmithKline Plc, Other Locations

GlaxoSmithKline Plc, Subsidiaries

GlaxoSmithKline Plc, Key Manufacturing Facilities

List of Figures

GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2015

GlaxoSmithKline Plc - Pipeline by Stage of Development, 2015

GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2015

GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2015

GlaxoSmithKline Plc - Partnered Products in Pipeline, 2015

GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2015

GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2015

GlaxoSmithKline Plc - Pipeline by Top 10 Route of Administration, 2015

GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2015

GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll